Amicus Therapeutics Inc (NASDAQ: FOLD) stock jumped 2.41% on Monday to $11.04 against a previous-day closing price of $10.78. With 1.81 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.36 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.17 whereas the lowest price it dropped to was $10.72. The 52-week range on FOLD shows that it touched its highest point at $14.10 and its lowest point at $9.70 during that stretch. It currently has a 1-year price target of $17.90. Beta for the stock currently stands at 0.83.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of FOLD was up-trending over the past week, with a rise of 7.50%, but this was up by 1.28% over a month. Three-month performance dropped to -11.47% while six-month performance fell -6.44%. The stock gained 0.64% in the past year, while it has lost -9.58% so far this year. A look at the trailing 12-month EPS for FOLD yields -0.60 with Next year EPS estimates of 0.11. For the next quarter, that number is -0.06. This implies an EPS growth rate of 45.17% for this year and 123.39% for next year.
Float and Shares Shorts:
At present, 293.25 million FOLD shares are outstanding with a float of 284.20 million shares on hand for trading. On Oct 30, 2023, short shares totaled 22.56 million, which was 7.69% higher than short shares on Sep 28, 2023. In addition to Mr. John F. Crowley as the firm’s Executive Chairman, Mr. Bradley L. Campbell M.B.A. serves as its CEO, President & Director.
Through their ownership of 105.51% of FOLD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 57.89% of FOLD, in contrast to 46.84% held by mutual funds. Shares owned by individuals account for 23.52%. As the largest shareholder in FOLD with 9.65% of the stake, Perceptive Advisors LLC holds 27,692,917 shares worth 27,692,917. A second-largest stockholder of FOLD, Avoro Capital Advisor LLC, holds 27,400,000 shares, controlling over 9.54% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in FOLD, holding 26,380,622 shares or 9.19% stake. With a 3.13% stake in FOLD, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 8,989,057 shares are owned by the mutual fund manager. The Vanguard Small Cap Index Fund, which owns about 2.58% of FOLD stock, is the second-largest Mutual Fund holder. It holds 7,409,727 shares valued at 81.28 million. Janus Henderson Contrarian Fund holds 2.52% of the stake in FOLD, owning 7,245,378 shares worth 79.48 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for FOLD since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With FOLD analysts setting a high price target of $21.00 and a low target of $12.00, the average target price over the next 12 months is $17.90. Based on these targets, FOLD could surge 90.22% to reach the target high and rise by 8.7% to reach the target low. Reaching the average price target will result in a growth of 62.14% from current levels.
Summary of Insider Activity:
Insiders traded FOLD stock several times over the past three months with 2 Buys and 7 Sells. In these transactions, 23,400 shares were bought while 47,925 shares were sold. The number of buy transactions has increased to 42 while that of sell transactions has risen to 74 over the past year. The total number of shares bought during that period was 1,730,782 while 1,129,507 shares were sold.